Climene, which contains the active ingredient estradiol valerate, is applied across domains where additional symptomatic support is needed. The treatment is used to address symptoms related to systemic imbalance that women experience during and after menopause.

The active ingredient is commonly used to help with key menopausal manifestations, such as hot flashes (vasomotor symptoms) and vulvar and vaginal atrophy. This treatment may assist with managing groups of symptoms that appear suddenly or fluctuate, and is considered relevant when supportive symptom management is appropriate. It provides supportive relief when symptoms interfere with routine activities.

The medication contributes to easing the overall symptom load associated with heightened discomfort, and may help patients cope more steadily with symptom fluctuations related to conditions characterized by periods of heightened symptoms. The treatment may assist with managing symptoms during episodes of heightened discomfort. As a benefit, “it supports general well-being during symptomatic phases,” contributing to improved comfort during symptomatic periods.

Quick Fact: Supports Symptom Management during temporary physiological imbalance

Regulatory References

1. NIH MedlinePlus Drug Information

Official Population Eligibility for Климен

Regulatory documentation strictly defines who can and cannot use Климен (estradiol valerate and cyproterone acetate) based on physiological status, age, and existing medical history.

Category	Official Regulatory Statement
Populations for whom use is allowed	Postmenopausal women with an intact uterus suffering from climacteric symptomatology [1.1].
Populations for whom use is contraindicated	History of breast cancer, liver tumours, venous/arterial thromboembolic disease (e.g., DVT, stroke), meningioma, untreated endometrial hyperplasia, or severe hepatic disease [1.1, 1.3].
Age-related eligibility rules	Not indicated for use in children and adolescents. No data necessitates dose adjustment in older adults [1.1].
Condition-specific eligibility rules	Contraindicated in severe disturbances of liver function; close monitoring is required for impaired liver function. Not specifically studied in renal impairment [1.1].
Pregnancy and lactation eligibility status	Use is contraindicated during both pregnancy and lactation [1.1].

The eligibility structure is built on absolute contraindications that exclude high-risk populations, such as those with certain malignancies or thromboembolic conditions. Use is formally limited to the postmenopausal age group and is prohibited when specific high-risk physiological states or comorbidities are present, as detailed in the regulatory label.

Interactions with other medicines and products

Official regulatory information for this combined hormonal product centers on pharmacokinetic interactions involving the Cytochrome P450 (CYP) enzyme system, particularly CYP3A4, which metabolizes the hormonal components.

Interacting Agents

Category	Specific Interacting Medicines/Substances
Enzyme Inducers	Phenytoin, Barbiturates (e.g., phenobarbital), Carbamazepine, Rifampicin, Rifabutin, Nevirapine, Efavirenz, Ritonavir, Nelfinavir, and the herbal product St. John's wort (Hypericum perforatum).
Enzyme Inhibitors	Erythromycin, Clarithromycin, Ketoconazole, Itraconazole, Ritonavir, Nelfinavir.
Other Drugs Affected	Lamotrigine, Exenatide.

Interaction Constraints

The most clinically significant interactions involve hepatic enzyme inducers. Co-administration with strong CYP3A4 inducers is officially documented to reduce the plasma concentrations of both estradiol and norethisterone acetate, which can lead to a loss of therapeutic effect. Conversely, co-administration with strong CYP3A4 inhibitors may increase the plasma concentrations of the hormones, potentially increasing the risk of adverse effects.

Additionally, the hormonal components can affect the metabolism of other drugs; for example, they can reduce exposure to lamotrigine by inducing its glucuronidation. Certain regulatory documents also advise spacing the administration of the hormonal product at least one hour before taking Exenatide due to its effect on gastric emptying and absorption.

How Климен Works

Selective Estrogen Receptor Modulation

Климен functions as a Selective Estrogen Receptor Modulator (SERM). Its foundational mechanism involves binding to and differentially modulating estrogen receptors (ERs) expressed across various target tissues. This tissue-selective activity determines whether the drug acts as an agonist or an antagonist of ER signaling.

---

Tissue-Specific Receptor Action

In tissues such as the hypothalamus and breast, Климен functions as an antagonist. By blocking the ERs, it prevents the activation of the receptor by endogenous estrogen, thereby modulating the downstream signaling cascade in these systems. Conversely, in bone tissue, the drug exhibits agonistic activity, directly activating the estrogen receptor.

---

Modulation of Bone Cell Activity

The agonistic action of Климен in the bone microenvironment influences the rate of bone remodeling. This involves a direct modulation of both osteoblast (bone-forming cells) and osteoclast (bone-resorbing cells) activity. This process ultimately leads to physiological changes in the overall tissue environment and, consequently, changes in bone mineral density.

Administration and Dosing Protocol

The administration of Климен follows a combined sequential hormone replacement therapy (HRT) protocol. The general guidance is to use the lowest effective dose for the shortest possible treatment period consistent with individual therapeutic goals.

Administration Details

Feature	Detail
Route of Administration	Oral. The film-coated tablets must be swallowed whole with sufficient liquid, without chewing.
Daily Frequency	One tablet is taken once daily.
Dosing Time	Tablets should be taken at approximately the same time of day to maintain a consistent schedule.

Cyclic Dosing Regimen

The standard adult regimen consists of a 28-day cycle. The medicine is supplied in a sequential calendar pack containing two types of active tablets:

• Estrogen-Only Phase: The first 11 tablets are white, each containing 2 mg estradiol valerate.
• Combined Phase: The following 10 tablets are pink, each containing 2 mg estradiol valerate and 1 mg cyproterone acetate.

Following these 21 active tablets, a 7-day tablet-free interval is observed before starting the next 28-day pack.

Procedural Guidelines

Treatment initiation is determined by the patient's status: patients not currently taking HRT or those with a menstrual cycle begin taking the first tablet on Day 5 of the cycle. Postmenopausal or amenorrhoeic patients can begin taking the tablets on any day. If a tablet is missed, it should be taken as soon as possible. However, if more than 24 hours have passed since the usual dosing time, the missed tablet must be discarded, and the current day's schedule must be maintained. The medication is not indicated for use in children or adolescents.

Research Evidence / Overview of Studies for Климен

This section provides a summary of the clinical research for the combined Hormone Replacement Therapy (HRT) containing estradiol valerate and cyproterone acetate. This overview focuses on what the studies explored and what patterns were observed in the research, without offering clinical advice, discussing safety, or making claims about individual outcomes.

---

Evidence for Use in Managing Menopausal Symptoms

Research exploring short-term changes in menopausal symptoms has primarily involved Randomized Controlled Trials (RCTs) and crossover studies, typically lasting 3 to 12 months. These trials were used in research examining patient-reported experiences in postmenopausal women with an intact uterus. Studies report how symptoms evolved in the observed populations during the treatment periods. Findings described patterns observed in the studies where women reported measurements indicating a reduction in the self-reported daily count of hot flashes and night sweats. Research studied for outcomes related to sleep quality and changes in Quality of Life (QoL) scores.

Evidence for Use in Postmenopausal Bone Health

The research base for bone health involves long-term observational follow-up trials as well as large-scale studies supporting the general class of systemic estrogen therapy. The combination therapy was studied for its role in managing bone density. Researchers examined markers where findings indicate patterns related to bone turnover and measurements of Bone Mineral Density (BMD), particularly at the spine and hip.

Monitoring protocols documented measurements indicating the preservation of BMD and bone mineral content over observation periods of up to six years. Studies explored associations between MHT and patterns of decreased fragility fracture risk in specific study populations.

---

Research Gaps and Areas of Uncertainty

Research highlights where evidence is limited or data for certain groups remain insufficient. Most of the foundational evidence was studied for women who initiate therapy relatively soon after menopause. There is limited information for long-term outcomes for women who start the treatment much later in life. While changes in biological markers were observed in some studies, definitive, large-scale long-term data on hard clinical cardiovascular outcomes for this specific combination are still emerging. Comparative evidence is lacking between this specific combination and all available alternative HRT or non-hormonal treatments.

Key Studies & References

1. NICE Guideline NG23: Menopause: diagnosis and management (Evidence review for HRT and symptom control)

Common questions about Климен (FAQ)

---

Q: Can I take Климен if I have thyroid problems?

Official product information indicates that the hormonal components in Климен may affect a protein called thyroid-binding globulin. This can influence the body's thyroid hormone levels.

If a patient is taking thyroid medication like levothyroxine, medical monitoring is necessary to check that hormone levels are maintained.

---

Q: Does taking Климен affect blood test results?

Yes, regulatory documents note that the medication may influence the results of certain laboratory tests. This includes parameters related to thyroid function, lipid (fat) metabolism, blood sugar levels, and blood coagulation factors.

Official information emphasizes communicating that you are taking Климен to the laboratory and your doctor prior to any testing.

---

Q: Can I stop taking Климен on my own?

According to official guidance, therapy changes, including stopping the medication, require medical supervision. Treatment plans are individualized, and stopping the medication may lead to the return of menopausal symptoms.

Regulatory guidelines state the medical plan must be reviewed before stopping the therapy.

---

Q: What happens if I accidentally take two tablets at once (overdose)?

Taking a single, accidental overdose may cause non-serious effects such as nausea, vomiting, and potential withdrawal bleeding. There is no specific treatment for overdose; management focuses on treating the symptoms.

Regulatory documents recommend seeking medical attention if an overdose is suspected.

---

Q: Can I take Климен after a hysterectomy (uterus removal)?

Климен is a combined hormonal product officially indicated for postmenopausal women who still have their uterus (an intact uterus). This is because the progestin component is included specifically to protect the uterine lining.

The product information states that women who have had a hysterectomy typically use estrogen-only therapy, as the progestin component is not needed.

---

Q: Does Климен affect libido?

Official reports from clinical trials indicate that changes in sexual desire (libido) have been reported as a possible undesirable effect.

These reported changes include both an increase and a decrease in libido.

---

Q: Does Климен contain lactose or other allergens?

Yes, the film-coated tablets contain lactose as an inactive ingredient (excipient). Official warnings state that patients with specific hereditary issues related to sugar intolerance (e.g., total lactase deficiency) are noted in regulatory information as requiring medical guidance before use.

---

Q: Does Климен affect the ability to drive?

Regulatory safety data generally indicates that the medication has no or negligible influence on a person's ability to drive vehicles or operate heavy machinery.

---

Q: How often should I get an examination while taking Климен?

Official precautions mandate that regular medical check-ups must be performed throughout the course of treatment. This includes a full physical examination, blood pressure measurement, and gynecological assessments (including breast exams), typically performed yearly.

---

Q: What should I do if I experience unusual side effects?

Official guidance is that all patients must promptly report any suspected or unusual adverse effects. Official guidance is that reporting suspected side effects to a treating physician or pharmacist should be done immediately.

---

Q: How does Климен affect blood pressure?

Blood pressure monitoring is a mandatory precaution because an increase in blood pressure has been reported in women taking hormone replacement therapy (HRT).

Official documentation requires blood pressure monitoring during regular check-ups.

---

Q: Does smoking affect the effectiveness or safety of Климен?

Regulatory safety documents state that smoking significantly increases the risk of serious side effects associated with hormonal therapy, particularly the formation of blood clots (thromboembolic events).

Due to the increased risk, regulatory information emphasizes that smoking cessation is an important safety consideration.

Storage and Disposal of Klimen

The storage and disposal of Klimen (Estradiol valerate and Cyproterone acetate) must adhere strictly to the conditions specified in official regulatory documents.

---

Required Storage Conditions

Requirement	Official Condition
Temperature	Store below 30°C (86°F).
Protection	Keep in the original blister pack and outer carton to protect from light and moisture.
Safety	Must be kept out of the sight and reach of children.

---

Disposal Instructions

Expired or unused Klimen tablets must not be thrown away with household waste or disposed of in wastewater. Official instructions require that disposal be managed through a pharmacist or an approved local medicine collection program.